Opioids and Migraine: Opioid Awareness and Frequency of Use among Turkish Migraineurs

Despite the inadequate evidence of effi cacy and safety of opioid use for the treatment of migraine, it has been reported that patients with moderate to severe migraine headaches are prescribed opioids. Migraineurs may experience serious health impacts from opioids such as headache-related disability, psychiatric and cardiovascular comorbidities. The reduction of the risk of opioid abuse and prevention of an opioid epidemic are important public health challenges. The aim of this study was to assess the awareness of opioid therapy for migraine and the frequency of use among Turkish patients with episodic and chronic migraine. Materials and methods: consecutive migraine patients were enrolled in this cross-sectional study. A semi-structured questionnaire was developed and used by the researchers to assess the patients’ awareness of an opiod treatment option and the frequency of use of opioids for migraine treatment. Results. One hundred two patients were enrolled, of which 72 had episodic migraine and 30 had chronic migraine. All subjects reported that they had not been offered or prescribed any kind of opioids by general practitioners and neurologists for their headache. Besides, only 7 % of patients declared that they had heard of opioid treatment for migraine but they had never consulted their doctors about its effects. Conclusions. Our fi ndings demonstrated that opioids were not preferred as an option for acute or preventive migraine treatment by Turkish migraineurs and their physicians. The reduction of opioid prescription will help to prevent the development of medication overuse and opiate-induced headaches and drug addiction.

1. Huskamp HA, Busch AB, Souza J, Uscher-Pines L, Rose S, Wilcock A, et al. How is telemedicine being used in opioid and other substance use disorder treatment? Health Aff (Millwood). 2018;37(12):1940–7. https://doi.org/10.1377/hlthaff.2018.05134

2. Goadsby PJ. Pathophysiology of migraine. Ann Indian Acad Neurol. 2012;15(Suppl 1):S15–22. https://doi.org/10.4103/0972-2327.99993

3. Stannard C. Opioid prescribing in the UK: can we avert a public health disaster? Br J Pain. 2012;6(1):7–8. https://doi.org/10.1177/2049463712439131

4. Goadsby PJ, Charbit AR, Andreou AP, Akerman S, Holland PR. Neurobiology of migraine. Neuroscience. 2009;161(2):327–41. https://doi.org/10.1016/j.neuroscience.2009.03.019

5. Buse DC, Pearlman SH, Reed ML, Serrano D, Ng-Mak DS, Lipton RB. Opioid use and dependence among persons with migraine: results of the AMPP study. Headache. 2012;52(1):18–36. https://doi.org/10.1111/j.1526-4610.2011.02050.x

6. Öztürk V. Acute treatment of migraine. Noro Psikiyatr Ars. 2013;50(Suppl 1):26–9. https://doi.org/10.4274/Npa.y7299

7. Knaggs RD, Stannard C. Opioid prescribing: balancing overconsumption and undersupply. Br J Pain. 2017;11(1):5. https://doi.org/10.1177/2049463716684055

8. Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migraine therapy. Springerplus. 2016;5:637. https://doi.org/10.1186/s40064-016-2211-8

9. Evers S, Áfra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–81. https://doi.org/10.1111/j.1468-1331.2009.02748.x

10. Friedman BW, Grosberg BM. Diagnosis and management of the primary headache disorders in the emergency department setting. Emerg Med Clin North Am. 2009;27(1):71–87. https://doi.org/10.1016/j.emc.2008.09.005

11. Colman I, Rothney A, Wright SC, Zilkalns B, Rowe BH. Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology. 2004;62(10):1695–700. https://doi.org/10.1212/01.wnl.0000127304.91605.ba

12. Colak D, Oguz A, Yazilitas D, Imamoglu IG, Altinbas M. Morphine: patient knowledge and attitudes in the central anatolia part of Turkey. Asian Pac J Cancer Prev. 2014;15(12):4983–8. https://doi.org/10.7314/apjcp.2014.15.12.4983

13. Şenel G, Oğuz G, Koçak N, Karaca Ş, Kaya M, Kadıoğulları N. Opioid use and the management of cancer patient pain in palliative care clinic. Agri. 2016;28(4):171–6. https://doi.org/10.5505/agri.2016.07830

14. Headache Classification Committee of the International Headache Society (IHS). The İnternational Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808. https://doi.org/10.1177/0333102413485658

15. Schiller M, Pyszora A, Graczyk M, Gajewska A, Krajnik M. Are the patients afraid of opioids? Pilot study of the patients with chronic cancer and non-malignant pain. Advances in Palliative Medicine. 2007;6(4):121–4.

16. Oğuz GT, Şenel GÖ, Silbermann M. Palliative care unit in an oncology hospital in Turkey. Clin Oncol. 2016;1:1157.

17. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(6):754–62. https://doi.org/10.1212/wnl.55.6.754

18. Casucci G, Cevoli S. Controversies in migraine treatment: opioids should be avoided. Neurol Sci. 2013;34(Suppl 1):S125–8. https://doi.org/10.1007/s10072-013-1395-8

19. Tornabene SV, Deutsch R, Davis DP, Chan TC, Vilke GM. Evaluating the use and timing of opioids for the treatment of migraine headaches in the emergency department. J Emerg Med. 2009;36(4):333–7. https://doi.org/10.1016/j.jemermed.2007.07.068

20. Ho TW, Rodgers A, Bigal ME. Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. Headache. 2009;49(3):395–403. https://doi.org/10.1111/j.1526-4610.2009.01346.x

21. Tepper SJ. Opioids should not be used in migraine. Headache. 2012;52(s1):30–4. https://doi.org/10.1111/j.1526-4610.2012.02140.x

22. Ossipov MH, Lai J, King T, Vanderah TW, Porreca F. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers. 2005;80(2-3):319–24. https://doi.org/10.1002/bip.20254

23. De Felice M, Ossipov MH, Porreca F. Persistent medication-induced neural adaptations, descending facilitation, and medication overuse headache. Curr Opin Neurol. 2011;24(3):193–6. https://doi.org/10.1097/WCO.0b013e328346af25

24. Wilkinson SM, Becker WJ, Heine JA. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache. 2001;41(3):303–9. https://doi.org/10.1046/j.1526-4610.2001.111006303.x

25. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48(8):1157–68. https://doi.org/10.1111/j.1526-4610.2008.01217.x

26. Clark DJ, Schumacher MA. America's opioid epidemic: supply and demand considerations. Anesth Analg. 2017;125(5):1667–74. https://doi.org/10.1213/ANE.0000000000002388

27. Huskamp HA, Busch AB, Souza J, Uscher-Pines L, Rose S, Wilcock A, et al. How is telemedicine being used in opioid and other substance use disorder treatment? Health Aff (Millwood). 2018;37(12):1940–7. https://doi.org/10.1377/hlthaff.2018.05134

28. Stannard C. Opioid prescribing in the UK: can we avert a public health disaster? Br J Pain. 2012;6(1):7–8. https://doi.org/10.1177/2049463712439131

29. Buse DC, Pearlman SH, Reed ML, Serrano D, Ng-Mak DS, Lipton RB. Opioid use and dependence among persons with migraine: results of the AMPP study. Headache. 2012;52(1):18–36. https://doi.org/10.1111/j.1526-4610.2011.02050.x

30. Knaggs RD, Stannard C. Opioid prescribing: balancing overconsumption and undersupply. Br J Pain. 2017;11(1):5. https://doi.org/10.1177/2049463716684055